Evidence map›Paper›PMID 40847620›Full record

ArticleAnnals of medicine2025

Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.

Haiyan Zhang, Yujie Li, Qing Zhang, Yubo Wang, Shuo Zhang, Xing Xing, Ziyuan Shen, Hui Liu, Wei Sang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haiyan ZhangDepartment of Hematology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, China.
Yujie LiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qing ZhangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yubo WangDepartment of Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shuo ZhangDepartment of Hematology, Linyi People's Hospital, Linyi, China.
Xing XingDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
Ziyuan ShenClinical Research Institute, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.ORCID 0000-0001-6989-9147
Hui LiuDepartment of Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei SangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.ORCID 0000-0002-1170-7074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the clinicopathological features and the prognostic values of the co-stimulatory molecules OX40 and the inducible T-cell co-stimulator (ICOS) in Extranodal Natural Killer/T-cell Lymphoma (ENKTL).

methods82 participants (median age 51 years, 26.8% female) were included in this study. OX40 and ICOS expression was detected using immunohistochemistry on paraffin‑embedded sections. The level of OX40 and ICOS expression was categorized into negative (0%, no staining) and positive groups. Kaplan-Meier analysis was used to estimate the probability of survival rates, and group comparisons were made using the Log-rank test.

resultsPositive staining for OX40 and ICOS was observed in 64 (78.0%) and 48 (58.5%) cases, respectively. The main differences between OX40-positive and OX40-negative were in the Chinese Southwest Oncology Group and Asia Lymphoma Study Group ENKTL (CA) stage, Korean Prognostic Index (KPI), CD68, PD1, PDL1, and CD152. Patients exhibiting positive OX40 expression demonstrated a statistically significant improvement in survival compared to the negative group (

conclusionsOur findings reveal that positive OX40 expression serves as an independent prognostic marker for improved survival of ENKTL, suggesting its potential utility in stratifying patient risk and optimizing treatment strategies. Future research should focus on the therapeutic targeting of OX40 in ENKTL.

Indexed as

Inducible T-Cell Co-Stimulator ProteinLymphoma, Extranodal NK-T-CellReceptors, OX40AdultAgedBiomarkers, TumorFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedPrognosisYoung AdultBiomarkers, TumorICOS protein, humanInducible T-Cell Co-Stimulator ProteinReceptors, OX40TNFRSF4 protein, humanExtranodal Natural killer/T-Cell Lymphomainducible T-cell co-stimulatorOX40prognosis

Identifiers

PMID40847620
PMCPMC12377112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.